PMID- 37275897
OWN - NLM
STAT- MEDLINE
DCOM- 20230607
LR  - 20230607
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - A novel antimicrobial peptide screened by a Bacillus subtilis expression system, 
      derived from Larimichthys crocea Ferritin H, exerting bactericidal and 
      parasiticidal activities.
PG  - 1168517
LID - 10.3389/fimmu.2023.1168517 [doi]
LID - 1168517
AB  - Antimicrobial peptides (AMPs) may be the most promising substitute for 
      antibiotics due to their effective antimicrobial activities and multiple function 
      mechanisms against pathogenic microorganisms. In this study, a novel AMP 
      containing 51 amino acids, named Lc1687, was screened from the large yellow 
      croaker (Larimichthys crocea) via a B. subtilis system. Bioinformatics and 
      circular dichroism (CD) analyses showed that Lc1687 is a novel anionic 
      amphiphilic alpha-helical peptide, which was derived from the C-terminal of a 
      Ferritin heavy subunit. The recombinant Lc1687 (named rLc1687) purified from 
      Escherichia coli exhibited strong activities against Gram-positive (Gram+) 
      bacterium Staphylococcus aureus, Gram-negative (Gram-) bacteria Vibrio 
      vulnificus, V. parahaemolyticus, and Scuticociliatida. Scanning electron 
      microscope (SEM) and transmission electron microscopy (TEM) revealed the possible 
      function mechanisms of this peptide, which is to target and disrupt the bacterial 
      cell membranes, including pore-forming, loss of fimbriae, and cytoplasm overflow, 
      whereas gel retardation assay revealed that peptide Lc1687 cannot bind bacterial 
      DNA. The peptide stability analysis showed that rLc1687 acts as a stable 
      antimicrobial agent against Gram+ and Gram- bacteria at temperatures ranging from 
      25 to 100 degrees C, pH 3-12, and UV radiation time ranging from 15 to 60 min. A 
      hemolytic activity assay confirmed that this peptide may serve as a potential 
      source for clinical medicine development. Taken together, Lc1687 is a novel AMP 
      as it is a firstly confirmed Ferritin fragment with antimicrobial activity. It is 
      also a promising agent for the development of peptide-based antibacterial and 
      anti-parasitic therapy.
CI  - Copyright (c) 2023 Chen, Lin, Liu, Tang, Wang and Zhang.
FAU - Chen, Meiling
AU  - Chen M
AD  - Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of 
      Agriculture and Rural Affairs, Jimei University, Xiamen, China.
FAU - Lin, Nengfeng
AU  - Lin N
AD  - Institute of Biotechnology, Fujian Academy of Agricultural Sciences, Fuzhou, 
      China.
FAU - Liu, Xiande
AU  - Liu X
AD  - Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of 
      Agriculture and Rural Affairs, Jimei University, Xiamen, China.
FAU - Tang, Xin
AU  - Tang X
AD  - Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of 
      Agriculture and Rural Affairs, Jimei University, Xiamen, China.
FAU - Wang, Zhiyong
AU  - Wang Z
AD  - Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of 
      Agriculture and Rural Affairs, Jimei University, Xiamen, China.
FAU - Zhang, Dongling
AU  - Zhang D
AD  - Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of 
      Agriculture and Rural Affairs, Jimei University, Xiamen, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230518
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antimicrobial Peptides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Peptides)
SB  - IM
MH  - Animals
MH  - Bacillus subtilis
MH  - Antimicrobial Peptides
MH  - Anti-Bacterial Agents/chemistry
MH  - *Anti-Infective Agents/pharmacology/metabolism
MH  - Peptides/metabolism
MH  - *Perciformes/genetics
PMC - PMC10232870
OTO - NOTNLM
OT  - Bacillus subtilis
OT  - Ferritin heavy subunit
OT  - Larimichthys crocea.
OT  - antibacterial
OT  - antimicrobial peptide
OT  - antiparasite
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/05 19:10
MHDA- 2023/06/07 06:42
PMCR- 2023/01/01
CRDT- 2023/06/05 12:23
PHST- 2023/02/17 00:00 [received]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/06/07 06:42 [medline]
PHST- 2023/06/05 19:10 [pubmed]
PHST- 2023/06/05 12:23 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1168517 [doi]
PST - epublish
SO  - Front Immunol. 2023 May 18;14:1168517. doi: 10.3389/fimmu.2023.1168517. 
      eCollection 2023.